Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Silverback Therapeutics, Inc. (SBTX)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
5.43+0.15 (+2.84%)
At close: 04:00PM EDT
5.43 0.00 (0.00%)
After hours: 04:01PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close5.28
Open5.37
Bid5.40 x 900
Ask5.50 x 1000
Day's Range5.25 - 5.44
52 Week Range2.80 - 11.19
Volume125,176
Avg. Volume291,425
Market Cap192.623M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for SBTX

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Silverback Therapeutics, Inc.
    Daily – Vickers Top Buyers & Sellers for 06/15/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Rating
    Fair Value
    Economic Moat
    4 months agoArgus Research
View more
  • Business Wire

    Silverback Therapeutics and ARS Pharmaceuticals Announce Merger

    SEATTLE & SAN DIEGO, July 21, 2022--Silverback Therapeutics, Inc. (Nasdaq: SBTX) ("Silverback") and ARS Pharmaceuticals, Inc. ("ARS") today announced that the companies have entered into a definitive agreement under which ARS will merge with Silverback in an all-stock transaction. The combined company will focus on the potential regulatory approval and commercialization of neffy, ARS’s investigational epinephrine nasal spray for the treatment of Type I allergic reactions including anaphylaxis. T

  • Business Wire

    Silverback Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

    SEATTLE, May 17, 2022--Silverback Therapeutics, Inc. (Nasdaq: SBTX) ("Silverback"), a biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases, today announced that Silverback management will participate in the H.C. Wainwright 24th Global Investment Conference from May 23-25, 2022.

  • Business Wire

    Silverback Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update

    SEATTLE, May 12, 2022--Silverback Therapeutics, Inc. (Nasdaq: SBTX) ("Silverback"), a biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases, today reported financial results for the first quarter ended March 31, 2022 and provided a business update.

Advertisement
Advertisement